CAVERJECT (alprostadil) by Pfizer is prostaglandin receptor agonists [moa]. First approved in 1995.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
CAVERJECT (alprostadil) is a prostaglandin analog administered via intracavernous injection that works as a prostaglandin receptor agonist to induce penile erection. It is indicated for erectile dysfunction and represents a direct-injection alternative to oral PDE5 inhibitors.
Product approaching loss of exclusivity with moderate competitive pressure (30), suggesting defensive positioning and potential organizational restructuring around this mature asset.
Prostaglandin Receptor Agonists
Prostaglandin Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Users Study Of The Caverject Delivery System
Caverject User Study
Alprostadil in Maculopathy Study (AIMS)
Topical Alprostadil for Female Sexual Arousal Disorder
Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV
Worked on CAVERJECT at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
CAVERJECT offers limited new career growth opportunities given its LOE-approaching status and zero linked job openings; roles focus on defending market share and managing decline. Career mobility on this product may be lateral or transitional rather than promotional.